Pyxis Oncology, Inc.

NASDAQ:PYXS

3.66 (USD) • At close September 18, 2024
Bedrijfsnaam Pyxis Oncology, Inc.
Symbool PYXS
Munteenheid USD
Prijs 3.66
Beurswaarde 217,487,971
Dividendpercentage 0%
52-weken bereik 1.35 - 6.85
Industrie Biotechnology
Sector Healthcare
CEO Dr. Lara S. Sullivan M.D., MBA
Website https://www.pyxisoncology.com

An error occurred while fetching data.

Over Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC),

Vergelijkbare Aandelen

Exagen Inc. logo

Exagen Inc.

XGN

2.84 USD

Longboard Pharmaceuticals, Inc. logo

Longboard Pharmaceuticals, Inc.

LBPH

29.31 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)